<DOC>
	<DOCNO>NCT02426281</DOCNO>
	<brief_summary>Nab-paclitaxel ( interchangeable ABRAXANE ABI-007 ) unique protein formulation noncrystalline , amorphous form paclitaxel insoluble particle state . Nab-paclitaxel design improve chemotherapeutic effect paclitaxel exploit endogenous transport pathway deliver high dos paclitaxel tumor reduce solvent-related hypersensitivity toxicity associate Taxol® ( paclitaxel ) injection , solvent Cremophor EL , ethanol vehicle . Nab-paclitaxel provide rapid tissue distribution increase tumor accumulation compare cremophor-EL paclitaxel . Mechanistically , albumin receptor-mediated transport across endothelium , bind interstitial protein , macropinocytic receptor-mediated uptake tumor cell well sequestration paclitaxel cremophor-EL may contribute observed difference . Furthermore , nab-paclitaxel synergizes gemcitabine preclinical model . The Cremophor EL-free medium enable nab-paclitaxel give high dose short duration without need premedication prevent solvent-related hypersensitivity reaction . As March 2014 , nab-paclitaxel approve trade name ABRAXANE 45 countries/regions , include US , Canada , India , European Union/European Economic Area , South Korea , China , Australia , Bhutan , United Arab Emirates , Nepal , New Zealand , Japan , Russia , Sri Lanka , Argentina , Hong Kong , Lebanon treatment patient metastatic breast cancer . ABRAXANE also approve first-line treatment locally advance metastatic non small cell lung cancer ( NSCLC ) US , Japan , Argentina , Australia , New Zealand , treatment advance gastric cancer Japan , first-line treatment metastatic adenocarcinoma pancreas US , EU/EEA , Australia , New Zealand Argentina .</brief_summary>
	<brief_title>Nab-pacliatxel Plus Gemcitabine Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description>Preclinical study demonstrate nab-paclitaxel may play role sensitize tumor chemotherapeutic agent specifically increase antitumor efficacy combine gemcitabine . While mechanism action synergy unclear , preclinical study generate hypothetical model . One hypothesis remodel weaken stroma barrier , allow chemotherapeutic agent well access tumor cell . Weakening tumor-stroma barrier particularly important cancer characterize dense stroma , pancreatic cancer . In mice primary patient derive pancreatic tumor xenograft , nab-paclitaxel plus gemcitabine versus gemcitabine alone result increased tumor regression deplete desmoplastic stroma observe less dense , disorganize , wisps collagen type1 fiber 4 week treatment . In study , intratumoral concentration gemcitabine increase 2.8-fold 5 day treatment nab-paclitaxel added gemcitabine . It hypothesize nab-paclitaxel may play role reduce dense stroma may contribute increased intratumoral gemcitabine uptake . Additional preclinical study genetically engineer mouse model pancreatic adenocarcinoma , coadministration nab-paclitaxel gemcitabine also demonstrate tumor regression increase intratumoral gemcitabine level 8 day treatment . Apoptosis tumor epithelial cell observe ; however , change stromal component collagen density short term treatment model . The increased intratumoral gemcitabine level attribute marked decrease primary gemcitabine metabolize enzyme , cytidine deaminase , nab-paclitaxel . Finally , recent clinical study subject resectable pancreatic cancer treat neoadjuvant nab-paclitaxel plus gemcitabine show reduction fibrotic collagenous stroma , support stroma active mechanism nab-paclitaxel . In clinical Phase 1/2 dose range study ( CA040 , NCT003980860 ) , nab-paclitaxel plus gemcitabine ( CA040 , NCT003980860 ) antitumor activity tolerability establish patient prior treatment metastatic pancreatic cancer . The maximum tolerate dose recommend dose study determine 125 mg/m2 nab-paclitaxel combination 1000 mg/m2 gemcitabine . In subsequent randomized international Phase 3 study ( MPACT , CA046 , NCT00394251 ) enrol 861 patient metastatic pancreatic cancer , nab-paclitaxel combination gemcitabine exhibit clinically meaningful , statistically significant improvement OS progression-free survival ( PFS ) . The median OS ( primary endpoint ) intent-to-treat population 8.5 month ( 95 % CI = 7.89-9.53 ) nab-paclitaxel/gemcitabine compare 6.7 month ( 95 % CI = 6.01-7.23 ) gemcitabine , p &lt; 0.0001 , HR = 0.72 ( 95 % CI = 0.617-0.835 ) . Long-term survival improve nab-paclitaxel/gemcitabine arm versus gemcitabine alone , 59 % increase 1 year ( 35 % versus 22 % ) double 2 year ( 9 % versus 4 % ) . The secondary ( PFS , overall response rate [ ORR ] ) efficacy endpoint show consistent , statistically significant improvement nab-paclitaxel/gemcitabine , support result primary analysis OS . Specifically , PFS ( independent review ) 5.5 month ( 95 % CI = 4.47-5.95 ) versus 3.7 month ( 95 % CI = 3.61-4.04 ) nab-paclitaxel/gemcitabine arm versus gemcitabine alone arm , respectively p &lt; 0.0001 ; HR =0 .69 ; 95 % CI = 0.581-0.821 ) . The improvement PFS correspond 31 % reduction risk progression death nab-paclitaxel/gemcitabine . Furthermore , study metastatic unresectable adenocarcinoma pancreas , subject combination arm therapy longer receive single agent gemcitabine , indicate disease improvement tolerable treatment . The suitability dose regimen confirm observation majority patient require dose reduction , 71 % nab-paclitaxel dos deliver start dose 125 mg/m2 . The safety profile regimens consistent previous report . Serious life threaten toxicity increase ; AEs acceptable manageable . The notable difference toxicity 2 treatment arm peripheral neuropathy , cumulative rapidly reversible dose delay reduction , neutropenia , manageable dose delay dose reduction . The incremental risk sepsis pneumonitis manage protocol amendment increase awareness , early diagnosis treatment reduce risk fatal outcomes . Since describe initial analysis MPACT study , update OS cutoff May 2013 show benefit continue improve nab-paclitaxel combination gemcitabine , 8.7 versus 6.6 median month , respectively . The updated survival rate also significantly favor nab-paclitaxel plus gemcitabine year 1 ( 35 % versus 22 % ) , year 2 ( 10 % versus 5 % ) , year 3 ( 4 % versus 0 % ) compare gemcitabine alone .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytologically confirm metastatic pancreatic ductal adenocarcinoma ( Islet cell neoplasms neuroendocrine carcinoma exclude ) 2 . ≥ 18 year age time sign informed consent document 3 . ECOG 01 4 . At least one measurable lesion accord recist v1.1 5 . No prior palliative chemotherapy treatment metastatic pancreatic cancer ( Prior treatment 5FU gemcitabine administer radiation sensitizer adjuvant setting allow treatment receive least 6 month enroll ) . 6 . Adequate BM function : ANC ≥1.5 × 109/L ; Platelet count ≥100,000/mm2 ( 100 × 109/L ) ; Hb ( Hb ) ≥9 g/dL . 7 . Adequate liver renal function ( obtain ≤14 day prior enroll ) : AST ( SGOT ) , ALT ( SGPT ) ≤2.5 × upper limit normal range ( ULN ) , unless liver metastases clearly present , ≤5 × ULN allow ; Total bilirubin 1.5 ≤ ULN ; Serum creatinine within normal limit calculate clearance ≥ 60 mL/min/1.73 m2 8 . Albumin level ≥ 3 g/dl 9 . Subjects asymptomatic jaundice prior Cycle 1 Day 1 10 . Subject sign Informed Consent Form ( ICF ) prior participation studyrelated activity . 11 . Female childbearing potential ( FCBP ) ( define sexually mature woman ( 1 ) undergone hysterectomy [ surgical removal uterus ] bilateral oophorectomy [ surgical removal ovary ] ( 2 ) naturally postmenopausal least 24 consecutive month [ ie , menses time precede 24 consecutive month ] ) must : Either commit true abstinence agree use 2 physicianapproved contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) IP ; 3 month follow last dose IP ; Has negative serum pregnancy test ( βhCG ) result screen 12 . Male subject must practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption , 6 month follow IP discontinuation , even undergone successful vasectomy 13 . Subject able adhere study visit schedule protocol requirement . 1 . Subject know symptomatic brain metastasis . 2 . History malignancy last 5 year . 3 . Breastfeeding pregnant female 4 . Patients plastic biliary stent ( Metal biliary stent allow . ) 5 . Subject active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 6 . Subject known historical active infection HIV , hepatitis B , hepatitis C. 7 . Subject undergone major surgery within 4 week prior Cycle 1 Day 1 treatment study . 8 . Subject experience recent myocardial infarction , include severe/unstable angina pectoris , coronary/peripheral artery bypass graft , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant electrocardiogram ( ECG ) abnormality , significant uncontrolled cardiovascular disease CHF , cerebrovascular accident transient ischemic attack , seizure disorder past year . 9 . Subject history allergy hypersensitivity study drug 10 . Subjects history connective tissue disorder ( eg , lupus , scleroderma , arteritis nodosa ) . 11 . Subjects history interstitial lung disease 12 . Any malignancy within 5 year prior enrollment , exception adequately treat insitu carcinoma prostate ( Gleason score ≤ 7 ) , cervix , uteri , nonmelanomatous skin cancer ( treatment complete 6 month prior enrollment ) . 13 . Patients &gt; Grade 1 preexist peripheral neuropathy ( per CTCAE ) 14 . Subject serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise subject 's safety study data integrity . 15 . Subject enrol clinical protocol investigational trial interventional agent assessment may interfere study procedure . 16 . Subject unwilling unable comply study procedures 17 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>